| __timestamp | Amphastar Pharmaceuticals, Inc. | Johnson & Johnson |
|---|---|---|
| Wednesday, January 1, 2014 | 159205000 | 22746000000 |
| Thursday, January 1, 2015 | 174172000 | 21536000000 |
| Friday, January 1, 2016 | 150976000 | 21685000000 |
| Sunday, January 1, 2017 | 149380000 | 25354000000 |
| Monday, January 1, 2018 | 187681000 | 27091000000 |
| Tuesday, January 1, 2019 | 190434000 | 27556000000 |
| Wednesday, January 1, 2020 | 206506000 | 28427000000 |
| Friday, January 1, 2021 | 238029000 | 23402000000 |
| Saturday, January 1, 2022 | 250127000 | 24596000000 |
| Sunday, January 1, 2023 | 293274000 | 26553000000 |
| Monday, January 1, 2024 | 27471000000 |
In pursuit of knowledge
In the ever-evolving landscape of pharmaceuticals, understanding the cost of revenue is crucial for assessing a company's financial health. This analysis delves into the cost of revenue trends for two industry titans: Johnson & Johnson and Amphastar Pharmaceuticals, Inc., from 2014 to 2023.
Over the past decade, Johnson & Johnson has consistently maintained a high cost of revenue, peaking in 2020 with a 28% increase from 2014. This reflects their expansive operations and robust product portfolio.
In contrast, Amphastar Pharmaceuticals has seen a remarkable 84% rise in cost of revenue over the same period. This surge underscores their aggressive growth strategy and increasing market presence.
These insights highlight the contrasting growth trajectories of these companies, offering a window into their strategic priorities and market dynamics.
Comparing Cost of Revenue Efficiency: Johnson & Johnson vs Gilead Sciences, Inc.
Cost of Revenue Comparison: Johnson & Johnson vs Regeneron Pharmaceuticals, Inc.
Johnson & Johnson vs Viatris Inc.: Efficiency in Cost of Revenue Explored
Cost Insights: Breaking Down Johnson & Johnson and Cytokinetics, Incorporated's Expenses
Johnson & Johnson vs Agios Pharmaceuticals, Inc.: Efficiency in Cost of Revenue Explored
Johnson & Johnson vs Galapagos NV: Efficiency in Cost of Revenue Explored
Johnson & Johnson and Amphastar Pharmaceuticals, Inc.: SG&A Spending Patterns Compared
Cost of Revenue Trends: Sanofi vs Amphastar Pharmaceuticals, Inc.
Cost Insights: Breaking Down Bio-Techne Corporation and Amphastar Pharmaceuticals, Inc.'s Expenses
Cost Insights: Breaking Down Xenon Pharmaceuticals Inc. and Amphastar Pharmaceuticals, Inc.'s Expenses
MorphoSys AG vs Amphastar Pharmaceuticals, Inc.: Efficiency in Cost of Revenue Explored
Cost of Revenue: Key Insights for Amphastar Pharmaceuticals, Inc. and Evotec SE